natgillin/translations-raw huggingface dataset:
Treatment with Revestive resulted in a 2.5 l/week reduction in parenteral nutrition requirements (from a pre-treatment baseline of 9.6 litres) versus 0.9 l/week (from a pre-treatment baseline of 10.7 litres) for placebo at 24 weeks.
Zdravljenje z zdravilom Revestive je imelo po 24 tednih za posledico zmanjšanje potrebe po parenteralni prehrani za 2,5 l/teden (glede na izhodiščno vrednost 9,6 litrov pred zdravljenjem) v primerjavi z 0,9 l/teden (glede na izhodiščno vrednost 10,7 litrov pred zdravljenjem) za placebo skupino.
Treatment with Revlimid must be monitored by doctors who have experience in the use of cancer medicines.
Zdravljenje z zdravilom Revlimid mora spremljati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Treatment with Revolade should be started and supervised by a doctor who has experience in treating blood diseases or chronic hepatitis C and its complications.
Zdravljenje z zdravilom Revolade lahko uvede in nadzoruje samo zdravnik, ki ima izkušnje z zdravljenjem krvnih obolenj ali kroničnega hepatitisa C in z njim povezanih zapletov.
Treatment with Ribavirin BioPartners should be started and monitored by a doctor who has experience in the management of long-term hepatitis C. The dose of Ribavirin BioPartners is based on the patient’s body weight, and ranges from three to seven tablets a day.
Zdravljenje z zdravilom Ribavirin BioPartners sme uvesti in spremljati le zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa C. Odmerek zdravila Ribavirin BioPartners je odvisen od bolnikove telesne mase in znaša od tri do sedem tablet na dan.
Treatment with Ribavirin Mylan should be started and monitored by a doctor who has experience in the management of long-term hepatitis C. The dose of Ribavirin Mylan is based on the patient’s body weight, and ranges from three to seven capsules a day.
Zdravljenje z zdravilom Ribavirin Mylan sme uvesti in spremljati le zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa C. Odmerek zdravila Ribavirin Mylan je odvisen od bolnikove telesne mase in znaša od tri do sedem kapsul na dan.
Treatment with Ribavirin Teva Pharma B.V. should be started and monitored by a doctor who has experience in the management of chronic hepatitis C.
Zdravljenje z zdravilom Ribavirin Teva Pharma B.V. mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa C.
Treatment with Rivastigmine 1 A Pharma should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Rivastigmine 1 A Pharma mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
Treatment with Rivastigmine 3M Health Care Ltd should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s dementia.
Zdravljenje z zdravilom Rivastigmin 3M Health Care Ltd mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve demence.
Treatment with Rivastigmine Actavis should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Rivastigmine Actavis mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
Treatment with Rivastigmine Hexal should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Rivastigmine Hexal mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
Treatment with Rivastigmine Sandoz should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Rivastigmine Sandoz mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
Treatment with Rivastigmine Teva should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Rivastigmine Teva mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
Treatment with romiplostim should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after four weeks of romiplostim therapy at the highest weekly dose of 10 μg/kg.
Zdravljenje z romiplostimom je treba prekiniti, če se število trombocitov po štirih tednih zdravljenja z največjim tedenskim odmerkom romiplostima 10 µg/kg ne poveča dovolj, da bi preprečilo klinično pomembne krvavitve.
Treatment with Ruconest should be started under the supervision of a doctor with experience in diagnosing and treating hereditary angioedema.
Zdravljenje z zdravilom Ruconest je treba začeti pod nadzorom zdravnika, ki ima izkušnje z diagnosticiranjem in zdravljenjem dednega angioedema.
Treatment with rufinamide should be initiated by a physician specialised in paediatrics or neurology with experience in the treatment of epilepsy.
Zdravljenje z rufinamidom naj uvede specialist pediater ali nevrolog z izkušnjami pri zdravljenju epilepsije.
Treatment with Samsca will be initiated in hospital
Zdravljenje z zdravilom Samsca se začne v bolnici.
Treatment with saxagliptin 5 mg once daily produced clinically relevant and statistically significant improvements in haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and postprandial glucose (PPG) compared to placebo in monotherapy, in combination with metformin (initial or add-on therapy), in combination with a sulphonylurea, and in combination with a thiazolidinedione (see Table 2).
Zdravljenje s 5 mg saksagliptina enkrat na dan je klinično pomembno in statistično značilno izboljšalo hemoglobin A1c (HbA1c), glukozo v plazmi na tešče in postprandialno glukozo v primerjavi s placebom v monoterapiji, v kombinaciji z metforminom (začetno ali dodatno zdravljenje), v kombinaciji s katero od sulfonilsečnin ali v kombinaciji s katerim od tiazolidindionov (glejte preglednico 3).
Treatment with selexipag 200–1,600 micrograms twice daily resulted in a 40% reduction (hazard ratio [HR] 0.60; 99% CI: 0.46, 0.78; one-sided log-rank p value < 0.0001) of the occurrence of morbidity or mortality events up to 7 days after last dose compared to placebo (Figure 1).
Zdravljenje s seleksipagom 200–1.600 mikrogramov dvakrat na dan je povzročilo 40-% zmanjšanje (razmerje tveganja [RT] 0,60; 99-% IZ: 0,46; 0,78; vrednost p enostranskega testa log-rank < 0,0001) pojava obolevnosti ali smrti do 7 dni po zadnjem odmerku v primerjavi s placebom (slika 1).
Treatment with Senshio can be restarted as soon as you regain your mobility and in consultation with your doctor.
Zdravljenje z zdravilom Senshio se lahko nadaljuje takoj, ko ste ponovno mobilni, v dogovoru z zdravnikom.
Treatment with Signifor can lead to rapid suppression of ACTH (adrenocorticotropic hormone) secretion.
Zdravljenje z zdravilom Signifor lahko povzroči nenadno zmanjšanje sproščanja ACTH (adrenokortikotropnega hormona).
Treatment with Signifor leads to rapid suppression of ACTH (adrenocorticotropic hormone) secretion in Cushing’s disease patients.
Pri bolnikih s Cushingovo boleznijo zdravljenje z zdravilom Signifor povzroči nenadno zmanjšanje sproščanja ACTH (adrenokortikotropnega hormona).
Treatment with Siklos should be initiated by a physician experienced in the management of Sickle Cell Syndrome.
Zdravljenje z zdravilom Siklos mora začeti zdravnik, izkušen v obravnavanju srpasto celičnega sindroma.
Treatment with Silapo must be started under the supervision of doctors who have experience in the management of patients with the conditions that the medicine is used for.
Zdravljenje z zdravilom Silapo je treba začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem bolnikov, katerih bolezenska stanja se zdravijo s tem zdravilom.
Treatment with Simponi must be initiated and supervised by a qualified doctor who has experience in the diagnosis and treatment of the diseases that Simponi is used to treat.
Zdravljenje z zdravilom Simponi mora uvesti in nadzorovati usposobljen zdravnik, ki ima izkušnje s področja diagnostike in zdravljenja bolezni, za zdravljenje katerih se uporablja zdravilo Simponi.
Treatment with Soliris should not alter anticoagulant management.
Zdravljenje z zdravilom Soliris ne sme spremeniti antikoagulantne terapije.
Treatment with Somavert should be initiated by a doctor who has experience in the treatment of acromegaly.
Zdravljenje z zdravilom Somavert mora uvesti zdravnik, ki ima izkušnje z zdravljenjem akromegalije.
Treatment with sorivudine or its chemically related analogues, such as brivudine (see section 4.5),
Zdravljenje s sorivudinom ali kemično podobnimi učinkovinami, kot je brivudin (glejte poglavje 4.5).
Treatment with sorivudine or its chemically related analogues, such as brivudine (see section 4.5).
Zdravljenje s sorivudinom ali kemično podobnimi učinkovinami, kot je brivudin (glejte poglavje 4.5).
Treatment with Sovaldi was as effective (67% patients - 171 out of 256 – tested negative) as peginterferon-based treatment (67% of patients - 162 out of 243).
Zdravljenje z zdravilom Sovaldi je bilo enako učinkovito (negativni izidi preiskav pri 67 % oziroma 171 od 256 bolnikov) kot zdravljenje na osnovi peginterferona (67 % oziroma 162 od 243 bolnikov).
Treatment with SPRYCEL is associated with anaemia, neutropaenia and thrombocytopaenia.
Zdravljenje z zdravilom SPRYCEL je bilo povezano z anemijo, nevtropenijo in trombocitopenijo.
Treatment with Sprycel should be started by a doctor who has experience in the diagnosis and treatment of leukaemia.
Zdravljenje z zdravilom Sprycel sme uvesti le zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem levkemije.
Treatment with STAYVEER should only be started and monitored by a doctor who has experience in the treatment of PAH or systemic sclerosis.
Zdravljenje z zdravilom STAYVEER mora uvesti in nadzirati zdravnik z izkušnjami v zdravljenju PAH ali sistemske skleroze.
Treatment with Stocrin should be started by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Stocrin lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Treatment with Sustiva should be started by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Sustiva lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Treatment with Sutent may lead to a higher risk of bleeding or lead to changes in the number of certain cells in the blood which may lead to anemia or affect the ability of your blood to clot.
Zdravljenje z zdravilom Sutent lahko povzroči večje tveganje za krvavitve ali privede do sprememb v številu določenih celic v krvi, kar lahko privede do slabokrvnosti ali vpliva na sposobnost strjevanja vaše krvi.
Treatment with systemic corticosteroids may be appropriate.
Morda je ustrezno zdravljenje s sistemskimi kortikosteroidi.
Treatment with Tafinlar must be started and supervised by a doctor experienced in the use of anticancer medicines.
Zdravljenje z zdravilom Tafinlar mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Treatment with Tagrisso may continue for as long as the disease improves or remains stable and the side effects are tolerable.
Zdravljenje z zdravilom Tagrisso se lahko nadaljuje, dokler se bolezen izboljšuje oziroma ostaja stabilna, neželeni učinki pa so znosni.
Treatment with Tarceva should be supervised by a doctor who has experience in the use of cancer medicines.
Zdravljenje z zdravilom Tarceva mora nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Treatment with Targretin should only be initiated and maintained by a doctor who has experience in the treatment of patients with CTCL.
Zdravljenje z zdravilom Targretin sme začeti in ga izvajati samo zdravnik z izkušnjami pri zdravljenju bolnikov s kožnim T-celičnim limfomom.
Treatment with Tasigna is associated with (National Cancer Institute Common Toxicity Criteria grade 3-4) thrombocytopenia, neutropenia and anaemia.
Zdravljenje z zdravilom Tasigna je povezano s trombocitopenijo, nevtropenijo in anemijo (stopnje 3-4 po enotnih kriterijih za vrednotenje neželenih učinkov Zveznega inštituta za raka - National Cancer Institute - Common Toxicity Criteria).
Treatment with Tasigna must be interrupted and blood count monitored.
Zdravljenje z zdravilom Tasigna je treba prekiniti in spremljati krvno sliko.
Treatment with Tasigna should be initiated by a doctor who has experience in the diagnosis and treatment of CML.
Zdravljenje z zdravilom Tasigna sme uvesti le zdravnik, ki ima izkušnje z diagnozo in zdravljenjem kronične mieloične levkemije.
Treatment with tenofovir disoproxil 245 mg (as fumarate) was also associated with significantly greater proportions of patients with HBV DNA < 400 copies/ml, when compared to adefovir dipivoxil 10 mg treatment.
Zdravljenje z 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) je bilo povezano tudi s pomembno večjim deležem bolnikov z < 400 kopij/ml HBV DNA, v primerjavi z zdravljenjem z 10 mg dipivoksiladefovirata.
Treatment with tenofovir disoproxil 245 mg (as fumarate) was associated with a mean change in serum HBV DNA from baseline, in the patients for whom there was 48-week data, of -5.74 log10 copies/ml (n = 18).
Pri bolnikih, za katere obstajajo podatki za 48 tednov, je bilo zdravljenje z 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) povezano s povprečno spremembo koncentracije HBV DNA v serumu od izhodiščne točke -5,74 log10 kopij/ml (n = 18).
Treatment with Teysuno is not recommended in patients with severe renal impairment due to possibly higher incidence of adverse events of the blood and lymphatic system and the possibility of unexpectedly higher exposure to 5-FU as a result of fluctuations in renal function in these patients, unless the benefits clearly outweigh the risks (see sections 4.2, 4.8 and 5.2).
Zdravljenje z zdravilom Teysuno pri bolnikih s hudo ledvično okvaro zaradi morebitno večje incidence neželenih dogodkov bolezni krvi in limfatičnega sistema ter možnosti nepričakovano večje izpostavljenosti 5-FU, kar je posledica nihanja v delovanju ledvic teh bolnikov, razen če je jasno, da so koristi večje od tveganja (glejte poglavja 4.2, 4.8 in 5.2).
Treatment with Thalidomide Celgene must be started and monitored under the supervision of a doctor who is skilled in using medicines that modulate the immune system or cancer medicines.
Zdravljenje z zdravilom Thalidomide Celgene mora uvesti in nadzorovati zdravnik, ki je usposobljen za uporabo zdravil, ki spreminjajo imunsko odzivnost, ali zdravil za zdravljenje raka.
Treatment with thalidomide may cause virus to become active again in patients who carry it, resulting in a recurrence of the infection.
Zdravljenje s talidomidom lahko povzroči, da postane virus pri bolnikih, ki ga prenašajo, spet aktiven, zato se okužba ponovi.
Treatment with the combination of temsirolimus and IFN-α resulted in a statistically significant increase in the incidence of certain Grade 3-4 adverse events (weight loss, anaemia, neutropaenia, thrombocytopaenia and mucosal inflammation) when compared to the adverse events observed in the IFN-α or temsirolimus-alone arms.
Zdravljenje s kombinacijo temsirolimusa in IFN-α je povzročilo statistično pomembno zvečanje incidence nekaterih neželenih učinkov 3.-4. stopnje (zmanjšanje telesne mase, anemija, nevtropenija, trombocitopenija in vnetje sluznic) v primerjavi z neželenimi učinki, ugotovljenimi v krakih z IFN-α samim ali temsirolimusom samim.
Treatment with the enzyme has been shown to reduce accumulation of Gb3 in many cell types including endothelial and parenchymal cells.
Pokazalo se je, da zdravljenje s tem encimom zmanjša kopičenje Gb3 v različnih vrstah celic, vključno z endotelijskimi in parenhimalnimi celicami.
Treatment with the other agents in the regimen should continue after completion of treatment with SIRTURO.
Po zaključku zdravljenja z zdravilom SIRTURO, je treba nadaljevati zdravljenje z drugimi učinkovinami, ki so del sheme.
Treatment with these standard medicines should continue as recommended by official guidelines after completion of Deltyba treatment.
Po koncu zdravljenja z zdravilom Deltyba se mora zdravljenje s temi standardnimi zdravili nadaljevati, kot priporočajo uradne smernice.
Treatment with this medicine is not recommended in some patients, such as those aged above 85 years or with moderately or severely impaired kidney function.
Zdravljenje s tem zdravilom ni priporočljivo pri nekaterih bolnikih, na primer bolnikih, starejših od 85 let, ali bolnikih z zmerno do hudo okvaro delovanja ledvic.
Treatment with this medicine may cause central serous chorioretinopathy, an eye disease that leads to blurred or distorted vision.
Zdravljenje s tem zdravilom lahko povzroči centralno serozno horioretinopatijo, očesno bolezen, ki povzroča zamegljen in popačen vid.
Treatment with Thymanax should only be prescribed after careful consideration of benefit and risk in patients with hepatic injury risk factors e.g. obesity/overweight/non-alcoholic fatty liver disease, diabetes, substantial alcohol intake and in patients receiving concomitant medicinal products associated with risk of hepatic injury.
Zdravljenje z zdravilom Thymanax lahko predpišete le po skrbnem pretehtanju koristi in tveganja pri bolnikih s prisotnimi dejavniki tveganja za poškodbo jeter, npr. debelost/prekomerna telesna masa/zamaščenost jeter nealkoholnega izvora, sladkorna bolezen, ter bolnikih, ki uživajo znatne količine alkohola ali sočasno jemljejo zdravila, ki jih spremlja tveganje za poškodbe jeter.
Treatment with TNF blockers such as Flixabi may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life-threatening in some cases.
Zdravljenje z zaviralci TNF, kakršen je Flixabi, lahko vodi do reaktivacije virusa hepatitisa B pri bolnikih, ki prenašajo ta virus, to pa je lahko v nekaterih primerih življenjsko nevarno.
Treatment with TNF blockers such as Inflectra may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life-threatening in some cases.
Zdravljenje z zaviralci TNF, kakršno je zdravilo Inflectra, lahko vodi do reaktivacije virusa hepatitisa B pri bolnikih, ki prenašajo ta virus, to pa je lahko v nekaterih primerih smrtno nevarno.
Treatment with TNF blockers such as Remicade may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life-threatening in some cases.
Zdravljenje z zaviralci TNF, kakršen je Remicade, lahko vodi do reaktivacije virusa hepatitisa B pri bolnikih, ki prenašajo ta virus, to pa je lahko v nekaterih primerih življenjsko nevarno.
Treatment with TNF blockers such as Remsima may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life-threatening in some cases.
Zdravljenje z zaviralci TNF, kakršno je zdravilo Remsima, lahko vodi do reaktivacije virusa hepatitisa B pri bolnikih, ki prenašajo ta virus, to pa je lahko v nekaterih primerih življenjsko nevarno.
Treatment with TNF blockers such as Simponi may result in reactivation of HBV in patients who carry this virus, which can be life-threatening in some cases.
Zdravljenje z zaviralci TNF, kakršen je Simponi, lahko namreč vodi do reaktivacije HBV pri bolnikih, ki prenašajo ta virus, to pa je lahko v nekaterih primerih tudi življenjsko nevarno.
Treatment with TOBI Podhaler should be continued on a cyclical basis for as long as the physician considers the patient is gaining clinical benefit from the treatment with TOBI Podhaler.
S cikličnim zdravljenjem z zdravilom TOBI Podhaler je treba nadaljevati, dokler je zdravljenje s zdravilom TOBI Podhaler po zdravnikovi presoji klinično koristno za bolnika.
Treatment with tolvaptan should be initiated at a dose of 15 mg once daily.
Zdravljenje s tolvaptanom je treba začeti z odmerkom 15 mg enkrat dnevno.
Treatment with Torisel should continue until the patient does not benefit from the medicine any more or has unacceptable side effects.
Zdravljenje z zdravilom Torisel se nadaljuje, dokler bolniku klinično koristi ali dokler se ne pojavijo nesprejemljivi neželeni učinki.
Treatment with Torisel should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.
Zdravljenje z zdravilom Torisel naj se nadaljuje, dokler bolniku ne preneha klinično koristiti ali dokler se ne pojavi nesprejemljiva toksičnost.
Treatment with Tracleer should only be started and monitored by a doctor who has experience in the treatment of PAH or systemic sclerosis.
Zdravljenje z zdravilom Tracleer mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem pljučne arterijske hipertenzije ali sistemske skleroze.
Treatment with trametinib monotherapy or in combination with dabrafenib should be used with caution in patients with risk factors for gastrointestinal perforation, including history of diverticulitis, metastases to the gastrointestinal tract and concomitant use of medications with a recognised risk of gastrointestinal perforation.
Previdnost je potrebna pri uporabi trametiniba v monoterapiji ali v kombinaciji z dabrafenibom pri bolnikih z dejavniki tveganja za perforacijo prebavil, kot so divertikulitis v anamnezi, metastaze v prebavnem traktu ali sočasna uporaba zdravil z znanim tveganjem za perforacijo prebavil.
Treatment with Trifexis was compared with a dummy treatment containing no active substance.
Zdravljenje z zdravilom Trifexis so primerjali z zdravljenjem brez zdravilne učinkovine.
Treatment with TRISENOX must be interrupted, adjusted, or discontinued before the scheduled end of therapy at any time that a toxicity grade 3 or greater on the National Cancer Institute Common Toxicity Criteria is observed and judged to be possibly related to TRISENOX treatment.
Zdravljenje z zdravilom TRISENOX morate pred načrtovanim koncem terapije prekiniti, prilagoditi ali prenehati v katerem koli trenutku, ko opazite toksičnost 3. stopnje po splošnih merilih toksičnosti Narodnega instituta za rak in ocenite, da je morda povezana z zdravljenjem z zdravilom TRISENOX.
Treatment with Trizivir often causes a loss of fat from legs, arms and face (lipoatrophy).
Zdravljenje z zdravilom Trizivir pogosto povzroči izginjanje maščevja na nogah, rokah in obrazu (lipoatrofija).
Treatment with Trobalt starts with one 100 mg tablet three times a day for one week; the dose is then increased weekly by 50 mg per dose according to the patient’s response.
Zdravljenje z zdravilom Trobalt se začne z enotedenskim zdravljenjem z eno 100-miligramsko tableto trikrat na dan, nato pa se ta odmerek vsak teden poveča za 50 mg v skladu z bolnikovim odzivom.
Treatment with Truvada should be started by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Truvada lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Treatment with Tysabri should be started and continuously supervised by a doctor who is experienced in treating diseases of the nervous system and has access to a magnetic resonance imaging (MRI) scanner.
Zdravljenje z zdravilom Tysabri mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem nevroloških bolezni in ki ima na voljo napravo za magnetnoresonančno slikanje (MRI).